Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Journal of Crohn'S & Colitis|September 8, 2020
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter StudyMathurin Fumery, Laurent Peyrin-Biroulet, Stephane Nancey, et al.
Therapeutic Advances in Gastroenterology|August 9, 2024
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAIDBénédicte Caron, Philippe Seksik, Anthony Buisson, et al.
Alimentary Pharmacology & Therapeutics|April 16, 2020
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort studyAurélien Amiot, Jérôme Filippi, Vered Abitbol, et al.
Alimentary Pharmacology & Therapeutics|July 23, 2021
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort studyMathurin Fumery, Jérôme Filippi, Vered Abitbol, et al.
Journal of Crohn'S & Colitis|January 14, 2020
Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort StudyAntoine Martin, Maria Nachury, Laurent Peyrin-Biroulet, et al.
Alimentary Pharmacology & Therapeutics|December 21, 2020
Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort studyPauline Wils, Philippe Seksik, Carmen Stefanescu, et al.
Alimentary Pharmacology & Therapeutics|November 26, 2020
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAIDDoriane Broussard, Pauline Rivière, Joelle Bonnet, et al.
Inflammatory Bowel Diseases|February 27, 2016
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent MalignancyFlorian Poullenot, Philippe Seksik, Laurent Beaugerie, et al.
Scandinavian Journal of Gastroenterology|July 12, 2022
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort studyAntoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 14, 2020
Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID groupMaria Nachury, Yoram Bouhnik, Melanie Serrero, et al.
Pageof 6